TRT denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits the Quantity of Testosterone Replacement Therapy — and How to Appeal

Testosterone replacement therapy (TRT) is available in several FDA-approved formulations — injectables, topical gels, patches, pellets, and others — and UnitedHealthcare applies quantity limits that specify how much of a given formulation may be dispensed per fill or per month. A quantity-limit denial occurs when the prescription as written exceeds the plan's allowed amount: for example, a vial size, tube quantity, or injection frequency that goes beyond UHC's per-period limit.

### Why This Denial Is Appealable

Quantity limits are typically administrative parameters — not clinical determinations that the drug is inappropriate. They are set by the pharmacy benefit manager to align with a "standard" dosing regimen. If your prescriber has a clinical reason why the standard quantity is insufficient for you — for example, body weight or formulation characteristics that require a larger amount, or a dosing schedule validated by your clinical response — that medical rationale supports a quantity-limit exception. The appeal demonstrates that the medically necessary quantity differs from the administrative default.

### Federal Appeal Framework

• Internal appeal: File a formal written internal appeal. UHC must issue decisions within 30 days (standard) or 72 hours (expedited/urgent).
• External review (ACA §2719): After exhausting internal options, independent external review by an accredited IRO is available and evaluates the claim on clinical evidence.
• ERISA §503: Employer-plan members are entitled to full-and-fair review with access to the criteria and clinical rationale for the limit.
• Timeline: File external review within approximately four months of final internal denial. Expedited review is available when the standard timeline poses a health risk.

### Concrete Appeal Steps

1. Obtain UHC's published quantity-limit criteria for the specific TRT formulation prescribed. 2. Compare the prescribed quantity to the limit and identify the exact gap. 3. Ask your prescriber to document the clinical rationale for the prescribed quantity — referencing the FDA-approved prescribing label's dosing guidance, your clinical response, and any prescriber titration decisions. 4. Submit the internal appeal with the prescriber letter and FDA prescribing label. 5. Escalate to external review if the internal appeal is denied.

### Documentation to Gather

• Diagnosis and treatment history: Chart documentation establishing hypogonadism diagnosis and the current TRT regimen with clinical rationale.
• Prescriber dosing rationale: A letter explaining why the prescribed quantity is clinically required — referencing FDA labeling guidance on dosing, your monitored clinical response, and any adjustments made based on response.
• FDA prescribing label: The current label from DailyMed for the specific formulation, which includes dosing guidance that may support the prescribed quantity.
• Monitoring records: Lab results or office notes documenting clinical monitoring that led to the current prescribed dose and quantity.

### Criteria-Mapping Structure

Obtain UHC's quantity-limit policy for the specific TRT formulation and map each requirement:

| UHC Quantity-Limit Criterion | Supporting Documentation | |---|---| | [Copy each criterion from UHC policy] | [FDA label reference, prescriber letter, monitoring note] |

If UHC's limit is more restrictive than the FDA-approved dosing range in the prescribing label, highlight that discrepancy explicitly in the appeal — the FDA label is the authoritative clinical reference.